Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-3185-5
Abstract: In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far.… read more here.
Keywords: aml mds; dac; cell transplantation; decitabine ... See more keywords
Incidence, Risk Factors and Outcomes of Therapy-Related Myeloid Malignancies after Hematopoietic Cell Transplantation: Analysis of the Japan Society for Hematopoietic Cell Transplantation Late Complications and QOL Working Group
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.179
Abstract: Background Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) occur after hematopoietic cell transplantation (HCT). The incidence, risk factors and outcomes of t-AML/MDS among patients who underwent autologous or allogeneic HCT for a variety of… read more here.
Keywords: aml mds; cell transplantation; hematopoietic cell; transplantation ... See more keywords
Current status and trends in the diagnostics of AML and MDS.
Sign Up to like & getrecommendations! Published in 2018 at "Blood reviews"
DOI: 10.1016/j.blre.2018.04.008
Abstract: Diagnostics of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have recently been experiencing extensive modifications regarding the incorporation of next-generation sequencing (NGS) strategies into established diagnostic algorithms, classification and risk stratification systems, and minimal… read more here.
Keywords: aml mds; status trends; diagnostics aml; trends diagnostics ... See more keywords
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia research"
DOI: 10.1016/j.leukres.2020.106402
Abstract: INTRODUCTION Chromosome 17 abnormalities, especially disorders of the 17p region and including TP53 gene mutations, result in very low rates of cure for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) treated with… read more here.
Keywords: aml mds; chromosome abnormalities; myeloid leukemia; hct ... See more keywords
Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1840180
Abstract: Abstract Objectives This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. Methods Data were extracted from the Spanish Ministry of Health records via… read more here.
Keywords: aml mds; myeloid leukemia; claims database; management ... See more keywords
B-214 Mutational Landscapes of Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Database-Driven Comprehensive Myeloid Panel Analysis of DNA Variants and Gene Fusions
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Chemistry"
DOI: 10.1093/clinchem/hvae106.574
Abstract: Myeloid malignancies, including Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), are characterized by a complex spectrum of genetic mutations. These mutations play a critical role in the pathogenesis of the diseases and are essential… read more here.
Keywords: panel; dna variants; aml mds; gene fusions ... See more keywords
Application of m6A regulators to predict transformation from myelodysplastic syndrome to acute myeloid leukemia via machine learning
Sign Up to like & getrecommendations! Published in 2024 at "Medicine"
DOI: 10.1097/md.0000000000038897
Abstract: Myelodysplastic syndrome (MDS) frequently transforms into acute myeloid leukemia (AML). Predicting the risk of its transformation will help to make the treatment plan. Levels of expression of N6-methyladenosine (m6A) regulators is difference in patients with… read more here.
Keywords: m6a regulators; m6a; aml mds; model ... See more keywords
Abstract CT085: iCare 1: A prospective clinical trial to predict treatment response based on mutanome-informed computational biology in patients with AML and MDS
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct085
Abstract: Hypomethylating agents (HMAs) (azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Despite their widespread use, HMAs fail in the… read more here.
Keywords: clinical trial; aml mds; response; patients aml ... See more keywords
Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2018-10-880690
Abstract: This study was performed to assess the utility of tumor-derived fragmentary DNA, or circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid leukemia and myelodysplastic syndrome (AML/MDS) after undergoing myeloablative allogeneic… read more here.
Keywords: aml mds; allogeneic hematopoietic; circulating tumor; tumor dna ... See more keywords
Using Social Media to Highlight Unmet Needs in Patients with AML and MDS Ineligible for Intensive Chemotherapy: A Patient Centered Perspective
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-112922
Abstract: Objectives: For patients with AML/MDS who are ineligible for intensive chemotherapy, prognosis is poor and effective treatment options are limited, often leading to unmet medical needs in this population. A deeper understanding of the patient… read more here.
Keywords: chemotherapy; aml mds; information; patients caregivers ... See more keywords
The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in Combination with ATRA Is Tolerable and Has Anti-Leukemic Activity in Adult Patients with Relapsed/Refractory AML and MDS
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115411
Abstract: Introduction: Tranylcypromine (TCP) is an irreversible monoamine oxidase inhibitor, a potent antidepressant that has been in use since the 1960s. Additionally, TCP has been demonstrated to inhibit lysine-specific histone demethylase 1A (LSD1), which is highly… read more here.
Keywords: combination; aml mds; tcp; bid ... See more keywords